Molecular marker predicts patients most likely to benefit longest from two popular cancer drugs
Johns Hopkins scientists have identified a molecular marker called "Mig 6" that appears to accurately predict longer survival—up to two years—among patients prescribed two of the most widely used drugs in a class of anticancer ...
Sep 5, 2013
0
0